Chandra Bhagat Pharma Ltd vs Dipna Pharmachem Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Chandra Bhagat Pharma Ltd is ₹ 33 as of 27 Apr 15:30 . The P/E Ratio of Chandra Bhagat Pharma Ltd changed from 158.4 on March 2021 to 45.9 on March 2025 . This represents a CAGR of -21.94% over 5 yearsThe P/E Ratio of Dipna Pharmachem Ltd changed from 16.5 on March 2023 to 34.9 on March 2025 . This represents a CAGR of 28.37% over 3 years The Market Cap of Chandra Bhagat Pharma Ltd changed from ₹ 29.88 crore on March 2021 to ₹ 39.48 crore on March 2025 . This represents a CAGR of 5.73% over 5 yearsThe Market Cap of Dipna Pharmachem Ltd changed from ₹ 15.02 crore on March 2023 to ₹ 34.38 crore on March 2025 . This represents a CAGR of 31.79% over 3 years The Dividend Payout of Chandra Bhagat Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Dipna Pharmachem Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Chandra Bhagat Pharma Ltd

Chandra Bhagat Pharma Limited was incorporated as a Private Limited Company with the name 'Chandra Bhagat Pharma Private Limited' at Mumbai on March 10, 2003.
Consequent upon the conversion of the Company from Private Limited Company to Public Limited Company, the name of the Company was changed to 'Chandra Bhagat Pharma Limited' on March 20, 2019. The Company incorporated in March, 2003 by Mr. Hemant Bhagat and Late.
Shree Chandravadan Bhagat.
On April 1, 2003, the Company acquired the going concern business of M/s.
Chandra Bhagat Corporation, partnership firm along with all its assets and liabilities.

About Dipna Pharmachem Ltd

Dipan Pharmachem Limited was incorporated on July 19, 2011.
Subsequently, the Company name was changed to 'Dipna Pharmachem Private Limited' on March 29, 2012.
Later on, it was converted from Private Limited to Public Limited and the name of Company was changed to 'Dipna Pharmachem Limited' vide fresh Certificate of Incorporation issued by Registrar of Companies, Ahmedabad dated May 25, 2022. Dipna Pharmachem Limited is a trader, importer, and exporter in industrial Chemical and Pharmaceutical Raw materials, APIs, solvents, and Formulation since 2011.
Presently, its product portfolio comprises of 61 AIPs and AIPs intermediates such as Cephalosporins, Cardiovasculars, Anti - Bactaria, Quinolones, Veterinary, Anti - Virus, Anti - Inflammatory, Neuropsychiatry, Steroid Hormone, other etc.

FAQs for the comparison of Chandra Bhagat Pharma Ltd and Dipna Pharmachem Ltd

Which company has a larger market capitalization, Chandra Bhagat Pharma Ltd or Dipna Pharmachem Ltd?

Market cap of Chandra Bhagat Pharma Ltd is 24 Cr while Market cap of Dipna Pharmachem Ltd is 22 Cr

What are the key factors driving the stock performance of Chandra Bhagat Pharma Ltd and Dipna Pharmachem Ltd?

The stock performance of Chandra Bhagat Pharma Ltd and Dipna Pharmachem Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Chandra Bhagat Pharma Ltd and Dipna Pharmachem Ltd?

As of May 5, 2026, the Chandra Bhagat Pharma Ltd stock price is INR ₹33.0. On the other hand, Dipna Pharmachem Ltd stock price is INR ₹8.4.

How do dividend payouts of Chandra Bhagat Pharma Ltd and Dipna Pharmachem Ltd compare?

To compare the dividend payouts of Chandra Bhagat Pharma Ltd and Dipna Pharmachem Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.